Evolutionary genetic tools trace cancer clone lines

June 16, 1999

Sophisticated computational tools developed to trace species evolution by comparing DNA sequences have now been used to track the development of human cancer.

The collaboration by a USC team led by cancer researcher Darryl Shibata and computational biologist Simon Tavare casts doubt on conventional wisdom regarding the relationship between colorectal cancers (carcinomas) and the polyps (adenomas) which typically precede them.

The preliminary findings, if they can be confirmed, may have clinical significance in considering non-surgical options for treating polyps.

According to Shibata, an associate professor in the USC medical school department of pathology, oncologists have long believed that the development of colon cancer is a progressive and linear process, with a normal cell mutating into adenoma, and the adenoma subsequently mutating further into carcinoma. In this conventional model, the adenoma is the direct precursor or ancestor to the carcinoma.

But according to the new study, published in the June issue of the American Journal of Pathology, genetic evolution analysis indicates that adenoma and carcinoma lines can arise from a common precursor but subsequently develop in parallel. In this scenario, the adenoma is not the "mother" of the carcinoma but rather a cousin.

The finding suggests that the direct progenitor of cancer cells may not be the most prevalent cell in a polyp. The clone comprising the majority of cells in the adenoma is genetically a dead end with respect to the cancer. One important consequence is that in some cases cancer may arise without being preceded by polyps at all, that is, "the true progenitor may be occult," according to Shibata.

The researcher notes that precisely this scenario is sometimes seen when a patient with no symptoms or polyps at one examination is found a year later to have developed colon cancer. Traditionally, it had been thought that the initial examination simply missed finding polyps or that evolution from a polyp to a cancer occurred faster than usual.

The analysis was possible because the abnormal colon cells studied, adenomas and carcinomas alike, all share a specific mutation that destroys the cell's ability to edit and repair errors in DNA replication. As a result, such cells accumulate such errors at a rapid and constant rate.

"This gives us a mutational clock, which we can use to keep track of progressions in the daughter cell lines," says Shibata. The frequency of the changes allows current genetic technology to compare easily cell lines through successive generations in specific non-coding parts of the human genome known as microsatellites.

The genetic sequences analyzed normally change very slowly, and cells from most kinds of cancer wouldn't be expected to accumulate many changes in the lifetime of their human hosts. But such changes do occur and accumulate in successive generations of normal cells over geologic time. This is where Tavare, the George and Louise Kawamoto Chair In Biological Sciences and professor of mathematics in USC's college of letters, arts & sciences, had learned to analyze them to study the history of species.

As the universal informational molecule, DNA sequences can be analyzed and compared regardless of their origins. "While changes that would normally accumulate over millennia in normal cells accumulate over months in these mismatch repair deficient tumor cells," says Tavaré, "they can be analyzed using similar mathematical techniques."

The analysis, done on a number of cell samples from three different patients, shows that, at least in this group of samples, the carcinoma cells and adenoma cells had diverged far back in the cell lineage, long before carcinoma was seen.

Because polyps are routinely removed when found, the findings don't suggest great changes in clinical approach to disease, says Shibata "as physical removal would eliminate both occult and overt potential cancer precursors. However, attempts to shrink polyps with chemotherapy may not prevent cancer," since if the new analysis is correct, reductions in the sizes of polyps may reflect efficacy against the adenoma dead-ends and not in the extinction of the actual cancer lineage.

Shibata began the research after reading about work in computational biology and thinking that the techniques might be applicable to oncology, made contact with Tavare, an international authority on development of computational techniques in molecular evolution.

Extensive meetings were necessary to make the experiment work: "He knew so little about the way tumors grow, and I knew so little about his methods," said Shibata.

However, Shibata hopes to continue to work with Tavare and others to refine his technique to attempt to shed light on development of metastases, the deadly colonies sent out by initial growths. They want to ask, are these descendents of the early cancer line or are they only produced at a late stage of tumor development?

Shibata notes that current techniques can take advantage of powerful animal models, although "mice don't live long enough to match the time scale of human tumor evolution" he said.

But he is excited by the prospects opened by the work, which he says is the first time the full sophistication of the techniques developed to track evolutionary changes have been used to study cancers.
-end-
Collaborating with Shibata and Tavare were Jen-Lin Tsao of the USC Norris Cancer Center department of pathology, Reijo Salovaar and Lauri Aaltonen of the University of Helsinki department of pathology and medical genetics, Helsinki, Finland; and Jeremy R. Jass, of the University of Queensland, Medical School, Herston, Australia.

The research was supported by grants from the National Institutes of Health and the National Science Foundation.

University of Southern California

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.